Jing Wang

Jing Wang

Auto-generated profile, based on publicly available information

Jing Wang

State Key Laboratory of Natural and Biomimetic Drugs Department of Chemical Biology School of Pharmaceutical Sciences Peking University Beijing 100191 China

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2022 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
CLCong Liu
Cong Liu
HSHanxiao Sun
Hanxiao Sun
Yunpeng YiYunpeng Yi
Yunpeng Yi
WSWeiguo Shen
Weiguo Shen
KLKai Li
Kai Li
JWJing Wang
Jing Wang

22 September 2021 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
LCLin Chen
Lin Chen
NLNa Li
Na Li
MZMeiqi Zhang
Meiqi Zhang
MSMingming Sun
Mingming Sun
JBJiaxuan Bian
Jiaxuan Bian
JWJing Wang
Jing Wang

21 June 2022 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
FDFeixiang Ding
Feixiang Ding
FLFei Li
Fei Li
DTDongsheng Tang
Dongsheng Tang
BWBin Wang
Bin Wang
JLJunyan Liu
Junyan Liu
ZLZhaoqian Liu
Zhaoqian Liu

22 January 2024 in Nature Protocols
Verified
Journal Article
Closed access
PDF file
WSWeiguo Shen
Weiguo Shen
HSHanxiao Sun
Hanxiao Sun
CLCong Liu
Cong Liu
Yunpeng YiYunpeng Yi
Yunpeng Yi
YHYongkang Hou
Yongkang Hou
CYChengqi Yi
Chengqi Yi

1 January 2015 in Clinical Laboratory
Verified
Journal Article
Closed access
Jing LiuJing Liu
Jing Liu
XCXiaomin Cai
Xiaomin Cai
LXLiang Xie
Liang Xie
YTYi Tang
Yi Tang
JCJinghua Cheng
Jinghua Cheng
JGJianbin Gong
Jianbin Gong
Circulating cell-free mtDNA (ccf-mtDNA) is presumably derived from injured tissue or cells in the body and has been suggested to be a potential biomarker in several diseases. In the present study, we investigated whether ccf-mtDNA levels could serve as a biomarker of diabetic patients without Coronary Heart Disease (CHD) and correlate with their incidence to develop CHD. Ccf-mtDNA levels in plasma and the traditional CHD risk factors were determined in 50 type 2 diabetes (DM) with CHD and 50 DM without CHD patients and 50 age- and sex-matched healthy controls. MtDNA levels were assessed by measuring the NADH dehydrogenase 1 gene using quantitative real-time PCR. ROC curve analyses of plasma mtDNA in DM with or without CHD were also determined. Multivariate logistic regression analyses were conducted to determine the correlation between the mtDNA levels and traditional CHD risk factors. The plasma ccf-mtDNA levels and CRP were significantly elevated in DM compared with healthy controls, and a consistent increase of mtDNA in diabetes with CHD compared to those without CHD. The area under the ROC curves of mtDNA in DM patients versus DM patients with CHD and healthy controls was 0.843 and 0.898, respectively. Correlation analyses showed that the mtDNA levels were significantly correlated with that of C-reactive protein (CRP) in patients with CHD. Ccf-mtDNA was elevated in type 2 diabetes with CHD and correlated with CRP levels. Both may be considered a prognostic biomarker of CHD development.

10 April 2021 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
WWWeibo Wang
Weibo Wang
QWQingpeng Wei
Qingpeng Wei
JZJiayuan Zhang
Jiayuan Zhang
MZMeiqi Zhang
Meiqi Zhang
CWChuchen Wang
Chuchen Wang
JWJing Wang
Jing Wang